Klaria Interim Report

Klaria Interim report Q3 2022 1 July- 30 September 2022

Summary of the interm report

Third quarter of 2022

- Net sales amounted to 0.0 MSEK (0.0 MSEK)

- Other income amounted to 0.0 MSEK (0.0 MSEK)

- R&D costs for the period amounted to 10.9 MSEK (12.5 MSEK)

- Profit after tax amounted to -16.1 MSEK (-12.2 MSEK)

- Earnings per share for the quarter amounted to -0.27 SEK (-0.24 SEK)

- Cash flow from operating activities amounted to -3.6 MSEK (-13.7 MSEK)

- Cash and cash equivalents on the balance sheet date amounted to 6.7 MSEK (25.9 MSEK)

- Equity as of September 30 amounted to 39.3 MSEK (95.2 MSEK)

The Period January-September

- Net sales amounted to 0.0 MSEK (0.0 MSEK)

- Other income amounted to 4.1 MSEK (31.3 MSEK)

- R&D costs for the period amounted to 42.7 MSEK (35.4 MSEK)

- Profit after tax amounted to -50.9 MSEK (-11.4 MSEK)

- Earnings per share for the quarter amounted to -0.88 SEK (-0.22 SEK)

- Cash flow from operating activities amounted to -39.1 MSEK (-10.2 MSEK)

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.